Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith & Nephew Snats ( (SNN) ) has issued an update.
On October 22, 2025, BlackRock, Inc. crossed a significant threshold in its voting rights in Smith & Nephew, reaching a total of 7.18%. This change in holdings, notified on October 23, 2025, reflects a slight increase from their previous position and could impact Smith & Nephew’s shareholder dynamics and influence within the company.
The most recent analyst rating on (SNN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats’ strong financial performance and positive earnings call outlook are the primary drivers of its stock score. While technical indicators show mixed momentum, and valuation suggests the stock may be expensive, the company’s robust cash flow and strategic initiatives support a positive outlook. Challenges in emerging markets and potential tariff impacts are notable risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew is a UK-based company operating in the medical equipment industry, primarily focusing on the development and manufacturing of advanced medical devices for wound management, orthopedics, and sports medicine.
Average Trading Volume: 752,666
Technical Sentiment Signal: Buy
Current Market Cap: $15.46B
See more insights into SNN stock on TipRanks’ Stock Analysis page.